1246765-38-7

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-3,4-dihydroquinazolin-2(1H)-one is utilized as a non-selective antagonist for both α1 and α2 adrenergic receptors, which can be beneficial in treating conditions related to the adrenergic system, such as hypertension and other cardiovascular diseases.
Used in Neurological Applications:
6-BroMo-3,4-dihydroquinazolin-2(1H)-one is employed for its potential anticonvulsant and sedative properties, making it a candidate for the development of drugs to manage epilepsy and other neurological disorders characterized by seizures or excessive excitability.
Used in Antimicrobial Development:
6-Bromo-3,4-dihydroquinazolin-2(1H)-one has shown promise as an inhibitor of the enzyme para-aminobenzoate synthase, which plays a crucial role in folic acid production in bacteria. This makes it a potential candidate for the development of new antimicrobial agents targeting bacterial pathways essential for their survival.

Upstream product

• 39263-32-6 2-amino-5-bromobenzonitrile 
• 4403-69-4 2-amino-1-benzylamine 
• 66655-67-2 1,2,3,4-tetrahydroquinazolin-2-one 
• 771583-12-1 2-(aminomethyl)-4-bromoaniline 
• 32315-10-9 bis(trichloromethyl) carbonate 

Relevant academic research and scientific papers

6-PIPERAZINYL-3,4-DIHYDROQUINAZOLIN-2(1H)-ONES

A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones have been synthesized. The compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent D2 receptor antagonist and 5-HT1A receptor

Heteroatom insertion into 3,4-dihydro-1 H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase

Aldosterone synthase (CYP11B2) catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone. CYP11B2 is regarded as a new target for several cardiovascular diseases which are associated with chronically elevated aldosterone levels such as hypertension, congestive heart failure and myocardial fibrosis. In this paper, we optimized heterocycle substituted 3,4-dihydropyridin-2(1H)-ones as CYP11B inhibitors by systematic introduction of heteroatoms and by bioisosteric exchange of the lactame moiety by a sultame moiety. The most promising compounds regarding inhibition of human CYP11B2 and selectivity versus human enzymes CYP11B1, CYP17, and CYP19 were tested for inhibition of rat CYP11B2. Thus, we discovered compounds 4 and 9 which show potent inhibition of hCYP11B2 (IC50 1 nM) and the corresponding rat enzyme (4: 64%, 9: 51% inhibition, at 2. 2 μM).

Ynthesis of 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones

A series of new 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones have been synthesized. The described compounds are structurally related to adoprazine, a potential atypical antipsychotics bearing potent D2 receptor antagonist and 5-HT1A receptor agonist pro

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.